Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM)

被引：0

作者：

Schuchter, Lynn Mara

Kudchadkar, Ragini Reiney

Gonzalez, Rene

Lawrence, Donald P.

Sosman, Jeffrey Alan

Infante, Jeffrey R.

Daud, Adil

Kefford, Richard

Cebon, Jonathan S.

Sharfman, William Howard

Amaravadi, Ravi K.

Boasberg, Peter D.

Lewis, Karl D.

Flaherty, Keith

Ouellet, Danielle

Little, Shonda M.

Clark, Jennifer

Gibney, Geoffrey Thomas

Patel, Kiran

Hamid, Omid

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[3] UCHSC, Aurora, CO USA

[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Tennessee Oncol, Nashville, TN USA

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Westmead Hosp, Westmead, NSW 2145, Australia

[10] Melanoma Inst Australia, Westmead, NSW, Australia

[11] Austin Hlth, Melbourne, Vic, Australia

[12] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[13] Angeles Clin & Res Inst, Santa Monica, CA USA

[14] Univ Colorado, Ctr Canc, Aurora, CO USA

[15] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA

[16] GlaxoSmithKline, Res Triangle Pk, NC USA

[17] GlaxoSmithKline, Collegeville, PA USA

[18] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9066

引用

页数：1

共 37 条

[1] BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)
Sosman, Jeffrey Alan
Daud, Adil
Weber, Jeffrey S.
Kim, Kevin
Kefford, Richard
Flaherty, Keith
Infante, Jeffrey R.
Hamid, Omid
Cebon, Jonathan S.
Schuchter, Lynn Mara
McWilliams, Robert R.
Sznol, Mario
Sharfman, William Howard
Algazi, Alain Patrick
Lewis, Karl D.
Little, Shonda M.
Sun, Peng
Long, Georgina
Patel, Kiran
Gonzalez, Rene
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)
Cebon, Jonathan S.
Flaherty, Keith
Weber, Jeffrey S.
Kim, Kevin
Infante, Jeffrey R.
Daud, Adil
Hamid, Omid
Kefford, Richard
Schuchter, Lynn Mara
Sosman, Jeffrey Alan
Sznol, Mario
Sharfman, William Howard
Gonzalez, Rene
Andrews, Miles Cameron
Dronca, Roxana Stefania
Long, Georgina
Little, Shonda M.
Sun, Peng
Patel, Kiran
McWilliams, Robert R.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
Igor Puzanov
Journal of Translational Medicine, 13 (Suppl 1)
[4] Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
Daniele Ouellet
Nastya Kassir
Joannellyn Chiu
Mohamad-Samer Mouksassi
Cathrine Leonowens
Donna Cox
Douglas J. DeMarini
Olivia Gardner
Wendy Crist
Kiran Patel
Cancer Chemotherapy and Pharmacology, 2016, 77 : 807 - 817
[5] Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)
Puzanov, Igor
Callahan, Margaret K.
Linette, Gerald P.
Patel, Sapna Pradyuman
Luke, Jason J.
Sosman, Jeffrey Alan
Wolchok, Jedd D.
Hamid, Omid
Minor, David R.
Orford, Keith W.
Hug, Bruce A.
Ma, Bo
Matthys, Gemma M.
Hoos, Axel
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
Ouellet, Daniele
Kassir, Nastya
Chiu, Joannellyn
Mouksassi, Mohamad-Samer
Leonowens, Cathrine
Cox, Donna
DeMarini, Douglas J.
Gardner, Olivia
Crist, Wendy
Patel, Kiran
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 807 - 817
[7] Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kim, Kevin B.
Kefford, Richard
Pavlick, Anna C.
Infante, Jeffrey R.
Ribas, Antoni
Sosman, Jeffrey A.
Fecher, Leslie A.
Millward, Michael
McArthur, Grant A.
Hwu, Patrick
Gonzalez, Rene
Ott, Patrick A.
Long, Georgina V.
Gardner, Olivia S.
Ouellet, Daniele
Xu, Yanmei
DeMarini, Douglas J.
Le, Ngocdiep T.
Patel, Kiran
Lewis, Karl D.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 482 - 489
[8] Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma
Yamazaki, Naoya
Tsutsumida, Arata
Takahashi, Akira
Namikawa, Kenjiro
Yoshikawa, Shusuke
Fujiwara, Yutaka
Kondo, Shunsuke
Mukaiyama, Akihira
Zhang, Fanghong
Kiyohara, Yoshio
JOURNAL OF DERMATOLOGY, 2018, 45 (04): : 397 - 407
[9] Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study
Burton, E. M.
Amaria, R. N.
Glitza, I. C.
Shephard, M.
Diab, A.
Milton, D.
Patel, S.
Mcquade, J.
Wong, M.
Hwu, P.
Wargo, J.
Davies, M. A.
Tawbi, H. A.
ANNALS OF ONCOLOGY, 2019, 30
[10] Evaluating the Safety and Tolerability of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients with Metastatic BRAF V600E/K Mutation-positive Cutaneous Melanoma
Wang, T. W.
Smith, J. L.
Carlino, M.
Burmeister, B.
Pinkham, M. B.
Fogarty, G. B.
Christie, D.
Estall, V.
Shackleton, M.
Wolfe, R.
Phuong, T. L. T.
Paton, E. J.
Steel, V.
Williams, N. C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S133 - S134

← 1 2 3 4 →